Edinburgh Molecular Imaging Ltd

Edinburgh Molecular Imaging (EM Imaging) is a biotechnology startup founded in 2014 in the United Kingdom with a focus on enabling image-guided therapy. Their innovative molecular imaging technology, based on Fluorescent Imaging, aims to detect disease in real-time during interventional procedures, providing more accurate treatment while sparing healthy tissue. The company is dedicated to the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes, specifically target cancerous cells and other diseased tissue. This technology, which received a notable £3.10M Venture Round investment from Caribou Property on 17 December 2019, has the potential to provide clinicians with a clearer view and a more effective decision-making tool to benefit patients.